Skip to main content
    A

    Arcutis Biotherapeutics Inc (ARQT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $27.15
    -1.11 (-3.93%)

    Market Cap: $3.57B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Arcutis Biotherapeutics Inc (ARQT) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Arcutis Biotherapeutics (ARQT) is expected to report earnings on Feb 23, 2027. In the quarter ended Sep 30, 2026, Arcutis Biotherapeutics reported EPS of $0.06, below the $0.17 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    72%(21/29)
    Avg Surprise
    +13.68%

    Upcoming Estimates

    Reports Feb 23, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.19
    Range$0.14 - $0.33
    10 analysts
    Revenue Consensus
    $166.22M
    Range$157.68M - $173.36M
    9 analysts
    Reports May 4, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.06
    Range-$0.09 - $0.14
    4 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.12-52.2%
    60d ago$0.12-52.2%
    30d ago$0.12-52.2%
    7d ago$0.08-31.3%
    Current$0.06
    Revenue Consensus
    $145.53M
    Range$133.80M - $152.10M
    5 analysts

    Next Report

    ARQT has an expected report date of Feb 23, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 46.2% above the $0.13 reported for the quarter ended Dec 31, 2025.

    ARQT Earnings Call

    The latest ARQT earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 29 quarters below that had an estimate, ARQT beat 21, missed 7 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $143.92M, up 45.1% from $99.22M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.06$0.17$0.10 - $0.20-64.71%Miss0.0%60 up, 1 downNov 4, 2026$143.92M
    Jun 30, 2026$0.11$0.09$0.00 - $0.13+22.22%BeatN/A62 up, 0 downAug 5, 2026$129.86M
    Mar 31, 2026-$0.09-$0.06-$0.15 - $0.06-50.00%MissN/A51 up, 1 downMay 6, 2026$105.40M
    Dec 31, 2025$0.13$0.09-$0.02 - $0.17+46.73%BeatN/A73 up, 0 downFeb 25, 2026$129.50M
    Sep 30, 2025$0.06-$0.09-$0.11 - -$0.08+166.67%BeatN/A62 up, 0 downOct 28, 2025$99.22M
    Jun 30, 2025-$0.13-$0.16-$0.20 - -$0.11+18.75%BeatN/A62 up, 0 downAug 6, 2025$81.50M
    Mar 31, 2025-$0.20-$0.21-$0.24 - -$0.15+4.76%BeatN/A61 up, 1 downMay 6, 2025$65.85M
    Dec 31, 2024-$0.09-$0.26-$0.33 - -$0.19+65.95%BeatN/A75 up, 0 downFeb 25, 2025$71.36M
    Sep 30, 2024-$0.33-$0.42-$0.46 - -$0.36+21.43%BeatN/A71 up, 0 downNov 6, 2024$44.76M
    Jun 30, 2024-$0.42-$0.53-$0.56 - -$0.45+20.75%BeatN/A61 up, 0 downAug 14, 2024$30.86M
    Mar 31, 2024-$0.32-$0.73-$0.91 - -$0.60+56.16%BeatN/A52 up, 0 downMay 14, 2024$49.57M
    Dec 31, 2023-$0.72-$0.80-$0.96 - -$0.48+10.00%BeatN/A70 up, 0 downFeb 27, 2024$13.53M
    Sep 30, 2023-$0.73-$0.91-$1.30 - -$0.67+19.78%BeatN/A83 up, 0 downNov 3, 2023$38.11M
    Jun 30, 2023-$1.16-$1.25-$1.31 - -$1.19+7.20%BeatN/A81 up, 0 downAug 8, 2023$5.19M
    Mar 31, 2023-$1.31-$1.26-$1.43 - -$1.20-3.97%MissN/A90 up, 0 downMay 9, 2023$2.78M
    Dec 31, 2022-$1.18-$1.42-$1.71 - -$1.36+16.90%BeatN/A90 up, 1 downFeb 28, 2023$2.96M
    Sep 30, 2022-$1.89-$1.75-$1.94 - -$1.26-8.00%MissN/A80 up, 2 downNov 8, 2022$725000
    Jun 30, 2022-$1.31-$1.42-$1.50 - -$1.34+7.75%BeatN/A51 up, 0 downAug 4, 2022N/A
    Mar 31, 2022-$1.27-$1.52-$1.54 - -$1.42+16.45%BeatN/A50 up, 0 downMay 5, 2022N/A
    Dec 31, 2021-$1.42-$1.49-$2.19 - -$1.24+4.70%BeatN/A6N/AFeb 22, 2022N/A
    Sep 30, 2021-$1.14-$1.19-$1.53 - -$0.94+4.20%BeatN/A6N/ANov 4, 2021N/A
    Jun 30, 2021-$0.84-$0.93-$1.01 - -$0.81+9.68%BeatN/A6N/AAug 5, 2021N/A
    Mar 31, 2021-$0.76-$0.97-$1.24 - -$0.81+21.65%BeatN/A4N/AMay 4, 2021N/A
    Dec 31, 2020-$0.79-$0.86-$0.96 - -$0.75+8.14%BeatN/A5N/AFeb 16, 2021N/A
    Sep 30, 2020-$1.01-$0.90-$0.97 - -$0.82-12.22%MissN/A4N/ANov 5, 2020N/A
    Jun 30, 2020-$0.94-$0.84-$0.94 - -$0.72-11.90%MissN/A3N/AAug 11, 2020N/A
    Mar 31, 2020-$1.15-$0.85-$1.14 - -$0.75-35.29%MissN/A3N/AMay 12, 2020N/A
    Dec 31, 2019-$6.18-$9.21-$9.21 - -$9.21+32.90%BeatN/A1N/AJan 31, 2020N/A
    Sep 30, 2019-$7.60-$7.60N/A0.00%In lineN/AN/AN/ANov 27, 2019N/A
    Jun 30, 2019-$0.17N/AN/AN/AN/AN/AN/AN/ASep 9, 2019N/A
    Last 30 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.14, after -$1.16 the year before. It was -$13.95 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.14N/A
    Dec 31, 2024-$1.16N/A
    Dec 31, 2023-$3.92N/A
    Dec 31, 2022-$5.65N/A
    Dec 31, 2021-$4.16N/A
    Dec 31, 2020-$3.89N/A
    Dec 31, 2019-$13.95N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 11,000 words across 14 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 202611,09514
    2026Q2Jun 30, 20265,86013
    2026Q1Mar 31, 20266,67713
    2025Q4Dec 31, 202510,20414
    2025Q3Sep 30, 20259,4189
    2025Q2Jun 30, 20255,30813
    2025Q1Mar 31, 20258,47613
    2024Q4Dec 31, 20248,01413

    2026Q3 Earnings Call

    Opening remarks

    Brian Schoelkopf Head of Investor Relations Thank you, Michelle. Good afternoon, everyone, and thank you for joining us today to review our third quarter 2026 financial results and business update. Slides for today's call are available in the Investors section of the Arcutis website. Joining me on the call today are Frank Watanabe, President and CEO of Arcutis; Rob Lisicki, Chief Commercial Officer; Patrick Burnett, Chief Medical Officer; and Latha Vairavan, Chief Financial Officer. I would like to remind everyone that we will be making forward-looking statements during this call. These statements are subject to certain risks and uncertainties, and our actual results may differ. We encourage you to review all of the company's filings with the Securities and Exchange Commission, including descriptions of our business and risk factors. With that, I'll now turn the call over to Frank to begin today's call.

    Frank Watanabe President and CEO Thanks, Brian, and good afternoon, everybody. As always, we appreciate you joining us for our quarterly update call. It's hard to believe that we're now in the fourth and final quarter of 2026. As I start this afternoon, I'm going to start with a review of the business and the progress we've made in our third quarter as we continue to execute against our grow, expand, and build corporate strategy and to deliver on our mission to bring meaningful innovation to individuals living with chronic inflammatory skin diseases. I'll then take a couple of minutes to address a question that we've been getting a lot recently, namely our approach to the application of artificial intelligence at Arcutis. I'll then turn it over to Rob for a commercial update, then Patrick will provide an update on our R&D programs and initiatives, and we'll finish with a review of the quarter's financial results from Latha before we open it up to your questions. Now, I'm on Slide 5. It has been a year since we unveiled our three-pillar grow, expand, and build strategy to sustain near- and long-term corporate growth. In the third quarter, once again, we made notable progress across all three pillars. I'll start with the grow pillar, comprising activities that are designed to strengthen our core ZORYVE business across our three current indications: plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. In late September, we announced an incredibly exciting new partnership with World Champion gymnast Simone Biles to launch our Skin to Believe In awareness campaign. The goal of this ambitious multichannel campaign is to encourage the nearly 36 million Americans living with either eczema or seborrheic dermatitis to talk to their doctor about long-term steroid-free topical treatment options for their chronic skin diseases.

    Frequently Asked Questions About ARQT

    When is Arcutis Biotherapeutics's next earnings date?

    Arcutis Biotherapeutics's next earnings report is expected for Feb 23, 2027.

    Did ARQT beat earnings estimates last quarter?

    No. Arcutis Biotherapeutics reported EPS of $0.06 for the quarter ended Sep 30, 2026, below the $0.17 estimate by 64.71%.

    What EPS do analysts expect from ARQT next quarter?

    The consensus EPS estimate for Arcutis Biotherapeutics for the quarter ending Dec 31, 2026 is $0.19 from 10 analysts, with estimates from $0.14 to $0.33.

    How often does ARQT beat earnings estimates?

    Arcutis Biotherapeutics beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +26.30%.